CGTX
USDCognition Therapeutics Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$1.600
Haut
$1.630
Bas
$1.550
Volume
1.39M
Fondamentaux de l'Entreprise
Capitalisation Boursière
138.5M
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
5.54M
Bourse
NCM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Reaches 75% Enrollment Target
PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)
PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, closed
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative disorders -
Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, was
Actions Connexes
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.